中华临床医师杂志(电子版) 2017年2月,11卷3期

临床论著

血清Betatrophin预测非酒精性脂肪肝及其进展的作用

邵小娟1 金海涛2 胡文1 郝海荣1 张勇1 夏明峰3 周红文4 俞伟男1

223002 江苏省,徐州医科大学附属淮安医院 淮安市第二人民医院内分泌科1;710061 西安交通大学医学院2;200032 上海,复旦大学附属中山医院内分泌科3;210029 南京,江苏省人民医院内分泌科4
俞伟男,Email: hayuweinan@163.com

摘要:目的 研究促代谢因子(Betatrophin)在预测非酒精性脂肪肝(NAFLD)及其进展中的作用。方法 249例受试者进行超声定量脂肪含量(LFC)测定,分为三组:正常对照组:LFC<9.15% 84例;低脂肪含量脂肪肝组(LLFC):9.15%≤LFC≤20% 82例;高脂肪含量脂肪肝组(HLFC):LFC>20% 83例,收集受试者的临床资料,空腹抽静脉血检测血清Betatrophin及相关临床指标。采用单因素方差分析比较三组间各指标差异,Pearson相关分析Betatrophin与各指标间的相关性,多元线性逐步回归分析影响LFC的独立因素。结果 (1)正常对照组、LLFC、HLFC三组血清Betatrophin水平分别为253.95(117.96~419.53)pg/ml,250.82(104.27~422.79)pg/ml,286.47(110.77~431.86)pg/ml,HLFC组Betatrophin水平较正常对照组、LLFC组有明显升高,差别有统计学意义(P<0.05)。(2)相关分析显示,校正性别、年龄后Betatrophin与LFC呈正相关(r=0.213,P<0.01)。(3)多因素线性回归分析显示,血清Betatrophin水平是LFC独立影响因素(t=2.561,P<0.05)。结论 血清Betatrophin是NAFLD及其进展的独立危险因素,临床检测Betatrophin有助于对进展期NAFLD人群早期识别、干预,改善预后。

关键词:非酒精性脂肪肝; 肝脏脂肪定量; 血清促代谢因子

Function of Betatrophin in the prediction of nonalcoholic fatty liver and its progress

Shao Xiaojuan1, Jin Haitao2, Hu Wen1, Hao Hairong1, Zhang Yong1, Xia Mingfeng3, Zhou Hongwen4, Yu Weinan1

Department of Endocrinology, Affiliated Huai'an Hospital of Xuzhou Medical College, Huai'an 223002, China; 2Xi'an Jiaotong University, Xi'an 710061, China; 3Department of Endocrinology, Affiliated Zho
Yu Weinan, Email: hayuweinan@163.com

Abstract:  Objective To study the function of Betatrophin in the prediction of nonalcoholic fatty liver (NAFLD) and its progress. Methods A total of 249 subjects based on ultrasonic quantitative determination of fat content (LFC) were divided into three groups, control (LFC<9.15%, n=84), LLFC (9.15%≤LFC≤20%, n=82) and HLFC (LFC>20%, n=83). Anthropometric and biochemical examinations were performed. Betatrophin and clinical factors were measured by ELISA Kit. One-way ANOVA, Pearson correlation analysis and multivariate linear regression analysis were used to analyze the results. Results The levels of Betatrophin in control group, LLFC group and HLFC group were 253.95 (117.96-419.53) pg/ml, 250.82 (104.27-422.79) pg/ml, 286.47 (110.77-431.86) pg/ml, respectively. Betatrophin levels in HLFC group increased significantly compared with control group and LLFC group (P<0.05). Serum Betatrophin showed significant differences in the three groups (P<0.01). Adjusted by gender and age, serum Betatrophin levels were positively correlated with LFC (r=0.213, P<0.01). Multivariate linear regression analysis showed that the serum Betatrophin level was an independent risk factor for the LFC (t=2.561, P<0.05). Conclusions Betatrophin is an independent risk factor for NAFLD and its progress. Checking serum Betatrophin is helpful for the early diagnosis of NAFLD and improvement of prognosis.

Keywords:Non-alcoholic fatty liver disease; Liver fat content; Betatrophin

+ 字体 -

参考文献

  [1] Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease[J]. Digestive Diseases, 2010, 28(1): 155-161.

  [2] Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD[J]. Liver International, 2012, 32(8): 1242-1252.

  [3] Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic β cell proliferation[J]. Cell, 2013, 153(4): 747-758.

  [4] Fu Z, Berhane F, Fite A, et al. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity[J]. Sci Rep, 2014, 4: 5013.

  [5] Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease[J]. J Clin Endocrinol Metab, 2006, 91(12): 4753-4761.

  [6] 夏明锋, 高鑫. 无创定量肝脏脂肪含量的新方法[J]. 中华内分泌代谢杂志, 2012, 28(8): 611-613.

  [7] 沈会明, 项丹, 李嘉, 等. 2 型糖尿病患者超声定量肝脏脂肪含量的临床意义[J]. 中国糖尿病杂志, 2014, 22(11): 966-969.

  [8] Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68276 biopsies[J]. J Hepatol, 1986, 2(2): 165-173.

  [9] Tseng YH, Yeh YH, Chen WJ, et al. Emerging regulation and function of betatrophin[J]. Int J Mol Sci, 2014, 15(12): 23640-23657.

  [10] Arias-Loste MT, García-Unzueta MT, Llerena S, et al. Plasma betatrophin levels in patients with liver cirrhosis[J]. World J Gastroenterol, 2015, 21(37): 10662-10668.

  [11] Chalasani N, Wilson L, Kleiner DE, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2008, 48(5): 829-834.

  [12] 谢萍, 周新喜, 张琴. 非酒精性脂肪肝的发病机制和治疗[J]. 中西医结合学报, 2010, 8(3): 201-209.

  [13] Chen X, Lu P, He W, et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance[J]. J Clin Endocrinol Metab, 2015, 100(1): E96-100.

  [14] Uramoto H, Sugio K, Oyama T, et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance[J]. Lung Cancer, 2005, 49(1): 55-62.

  [15] Lee YH, Lee SG, Lee CJ, et al. Association between betatrophin/ ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies[J]. Sci Rep, 2016, 6: 24013.

  Cengiz M, Ozenirler S, Kocabiyik M. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis[J]. Eur J Gastroenterol Hepatol, 2016, 28(1): 57-63.

(编辑:戚红丹 收稿日期:2016-10-24)